SAN DIEGO, June 17 /PRNewswire/ -- Leading a trend of unprecedented growth in biotechnology innovation, targeted therapies with companion molecular diagnostics have built significant traction in the past year in terms of development and usage, according to a new Deloitte study released today at the 2008 BIO International Convention in San Diego.
Findings from the Deloitte report support the need to measure innovation in the market, in addition to the lab. Out of six biotechnology innovations measured, the study found that four (targeted therapies, monoclonal antibodies, radiotherapy and drug device combinations) advanced significantly in 2007, marking a year of unprecedented progress and commercial impact. Targeted therapies with companion molecular diagnostics have experienced the most profound surge in realization, rising 50 percent in just three years.
Developed to track the pace and progress of therapeutic-based technologies, the Deloitte report includes both quantitative research leveraging a proprietary index model and qualitative insights and analyses based on interviews with leading life sciences industry executives.
"Given the volatility and the pace of scientific discovery in recent years, there is a need for a fact-based analysis to better understand which innovations are emerging as the most promising and, conversely, which technologies are losing ground," said Matthew Hudes, U.S. managing principal, Biotechnology, for Deloitte Consulting LLP's Life Sciences & Health Care practice, and the director of the study. "As a first step toward more personalized treatments, targeted therapies with companion diagnostics are reaching more patients. However, there remain significant economic, reimbursement and regulatory challenges that could prevent valuable treatments from becoming available to people who need them."
Using data collected over the past six years, Deloitte researchers created a three-stage measurement model covering discovery, development and realization to measure the inputs and outputs of innovation during the process of bringing new products to market. The six key innovations were selected based on their impact on patient care and health outcomes: targeted therapies with companion molecular diagnostics, monoclonal antibodies (MAbs), stem cell therapy, RNA interference (RNAi), drug device combinations and radiotherapy.
Additional benchmark findings based on data from the Deloitte report
-- Targeted therapies with companion molecular diagnostics - Have quickly
progressed from idea to realization as a number of new products entered
the market in the last few years. Discovery innovation remains active
and development continues.
-- Monoclonal antibodies - Have achieved widespread clinical acceptance in
the past three years after more than 20 years of variable progress.
However, the volume of discovery innovations has dropped off as they
move into the next stage, development. New structures and methods have
resulted in a fresh set of innovations, some of which are already in
-- Stem cells - Have achieved a high level of discovery innovation over
the past six years; however realization and development have not yet
-- RNAi - As a newer technology in the area of therapeutic treatment, RNAi
experienced discovery innovation only in the last four years; however,
there has been modest development and no realization yet.
-- Drug-device combinations - Have achieved general acceptance over the
past six years, and as this trend toward convergence evolves, a second
wave of innovation suggests future realization activity.
-- Radiotherapy - A relatively mature innovation, radiotherapy has
experienced a recent burst of innovation over the past three years
resulting in rapid adoption of new applications.
Trends Across Three Stages of Innovation
In 2002, monoclonal antibodies were the highest achieving innovative technology in terms of discovery, while RNAi-based gene therapy was the least. By 2007, stem cells moved from the middle of the pack to achieving the highest discovery innovation index among the six technologies; RNAi moved up, and monoclonal antibodies moved down to a lower level of innovation. Radiotherapy remained relatively high throughout the index. The remaining technologies were the lowest and were nearly identical in 2007.
Radiotherapy was the highest achieving innovative technology in terms of development from 2002 to 2007. Marked by a more than 80 percent increase in the number of approvals from 18 in 2005 to 33 in 2006, radiotherapy experienced a large spike in development. The remaining technologies were near the minimum value of the index.
Stem cell and RNAi gene therapy were the highest achieving technology innovations in terms of final product realization. While they lack the maturity to make an immediate impact on the marketplace, both appear to be on the rise. Additionally, realization substantially increased over time for the remaining four technologies. From 2002 to 2007, the realization index increased by 39 percent, 34 percent, 48 percent and 31 percent for targeted therapy, monoclonal antibodies, radiotherapy and drug device combinations, respectively.
"Tracking innovation in the life sciences industry will not only be important to industry leaders and pundits, but also to consumers who are already driving major changes to how health care is delivered, as they seek more personalized options for care," said Paul Keckley, Ph.D., executive director of the Deloitte Center for Health Solutions.
Consumers' interest in life sciences and health care innovations was
illustrated by the Deloitte Center for Health Solutions' 2008 Survey of
Health Care Consumers. Representative findings from the survey of more than
3,000 U.S. consumers found:
-- Nearly 90 percent of consumers are interested in using a self-
monitoring device at home if they developed a condition requiring
-- Twenty percent used an alternative approach to treatment, such as
homeopathic, naturopathic, acupuncture, chiropractic, and bio-electric
therapies; 40 percent might do so in the future.
-- Twelve percent consulted an alternative health care practitioner (for
example, an herbalist, homeopath or chiropractor); 38 percent might do
so in the future.
-- Nine percent substituted an alternative or natural therapy for a
prescription medication; 32 percent might in the future.
-- Thirty-two percent prefer to choose doctors with an orientation toward
holistic or alternative treatments.
-- Fourteen percent are aware of biologic drugs; consumers did not express
a clear preference between biologic and traditional pharmaceuticals.
-- Nearly 40 percent would consider traveling to a foreign country to have
an elective procedure performed if they could save 50 percent or more
and be assured that the quality was equal to or better than what is
available in the United States.
"Life sciences firms should seek to develop products that respond to consumers' desires for improved capabilities to self-monitor and manage their own care, and address their interest in alternative and personalized treatment options, as well as non-conventional delivery models," said Terry Hisey, vice chairman and industry leader of Deloitte LLP's life sciences practice. "Insights from our research indicate that there are unmet consumer needs that present opportunities for pharmaceutical manufacturers, biotechnology firms, and medical product, technology and device manufacturers to fill the void and improve the overall quality of care."
Complete findings from the Deloitte Center for Health Solutions' 2008 Survey of Health Care Consumers can found at http://www.deloitte.com/us/healthcareconsumersurvey
As used in this document, "Deloitte" means Deloitte LLP and its
subsidiaries. Please see http://www.deloitte.com/about for a detailed description
of the legal structure of Deloitte LLP and its subsidiaries.
Event: BIO2008 Conference http://www.deloitte.com/us/BIO2008
Overview: Catch the Life Sciences Wave: A Deloitte Perspective
Profile: Meet Matthew Hudes, http://www.deloitte.com/dtt/employee_profile/0,1007,sid%253D2219%2526cid%253D1 07093,00.html
Marykate Reese Dana Christiansen
Public Relations Hill & Knowlton
Deloitte 212 885 0359 (o)
203 257 0452 (m) 215 534 3250 (m)
Copyright©2008 PR Newswire.
All rights reserved